Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: A randomized international trial

Maribel Rodriguez-Torres, Jihad Slim, Laveeza Bhatti, Richard Sterling, Mark Sulkowski, Tarek Hassanein, Rosário Serrão, Ricard Sola, Anne Bertasso, Sharon Passe, Saray Stancic

Research output: Contribution to journalArticle

Abstract

Background: The safety and efficacy of weight-based ribavirin (RBV) dosing regimens in patients with HIV-HCV coinfection has not been demonstrated in randomized clinical trials. Objective: This randomized, double-blind, international, parallel-group study in specialist outpatient clinics in the United States, Spain, and Portugal compares the efficacy and safety of 2 RBV dose regimens (800 mg/day and 1000/1200 mg/day) combined with peginterferon alfa-2a (40KD) in patients with HIV-HCV (genotype 1) coinfection. Methods: Patients with HIV-HCV coinfec-tion, quantifiable HCV RNA in serum, HCV genotype-1 infection, compensated liver disease, and stable HIV disease (CD4+ count ≥100 cells/μL) with or without ongoing antiretroviral therapy were randomized to 48 weeks' treatment with RBV at standard dose (800 mg/day) or weight-based dose (1000 mg/day for patients weighing

Original languageEnglish (US)
Pages (from-to)142-152
Number of pages11
JournalHIV Clinical Trials
Volume13
Issue number3
DOIs
StatePublished - Jan 1 2012

Fingerprint

Ribavirin
Genotype
HIV
Coinfection
Safety
Weights and Measures
Portugal
CD4 Lymphocyte Count
Ambulatory Care Facilities
Spain
Liver Diseases
Randomized Controlled Trials
RNA
peginterferon alfa-2a
Therapeutics
Infection
Serum

Keywords

  • HCV
  • HIV
  • HIV-HCV co-infection
  • peginterferon alfa-2a
  • randomized controlled trial
  • ribavirin

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients : A randomized international trial. / Rodriguez-Torres, Maribel; Slim, Jihad; Bhatti, Laveeza; Sterling, Richard; Sulkowski, Mark; Hassanein, Tarek; Serrão, Rosário; Sola, Ricard; Bertasso, Anne; Passe, Sharon; Stancic, Saray.

In: HIV Clinical Trials, Vol. 13, No. 3, 01.01.2012, p. 142-152.

Research output: Contribution to journalArticle

Rodriguez-Torres, M, Slim, J, Bhatti, L, Sterling, R, Sulkowski, M, Hassanein, T, Serrão, R, Sola, R, Bertasso, A, Passe, S & Stancic, S 2012, 'Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: A randomized international trial', HIV Clinical Trials, vol. 13, no. 3, pp. 142-152. https://doi.org/10.1310/hct1303-142
Rodriguez-Torres, Maribel ; Slim, Jihad ; Bhatti, Laveeza ; Sterling, Richard ; Sulkowski, Mark ; Hassanein, Tarek ; Serrão, Rosário ; Sola, Ricard ; Bertasso, Anne ; Passe, Sharon ; Stancic, Saray. / Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients : A randomized international trial. In: HIV Clinical Trials. 2012 ; Vol. 13, No. 3. pp. 142-152.
@article{0c26eb662f364192bfef2ad6e07aac65,
title = "Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: A randomized international trial",
abstract = "Background: The safety and efficacy of weight-based ribavirin (RBV) dosing regimens in patients with HIV-HCV coinfection has not been demonstrated in randomized clinical trials. Objective: This randomized, double-blind, international, parallel-group study in specialist outpatient clinics in the United States, Spain, and Portugal compares the efficacy and safety of 2 RBV dose regimens (800 mg/day and 1000/1200 mg/day) combined with peginterferon alfa-2a (40KD) in patients with HIV-HCV (genotype 1) coinfection. Methods: Patients with HIV-HCV coinfec-tion, quantifiable HCV RNA in serum, HCV genotype-1 infection, compensated liver disease, and stable HIV disease (CD4+ count ≥100 cells/μL) with or without ongoing antiretroviral therapy were randomized to 48 weeks' treatment with RBV at standard dose (800 mg/day) or weight-based dose (1000 mg/day for patients weighing",
keywords = "HCV, HIV, HIV-HCV co-infection, peginterferon alfa-2a, randomized controlled trial, ribavirin",
author = "Maribel Rodriguez-Torres and Jihad Slim and Laveeza Bhatti and Richard Sterling and Mark Sulkowski and Tarek Hassanein and Ros{\'a}rio Serr{\~a}o and Ricard Sola and Anne Bertasso and Sharon Passe and Saray Stancic",
year = "2012",
month = "1",
day = "1",
doi = "10.1310/hct1303-142",
language = "English (US)",
volume = "13",
pages = "142--152",
journal = "HIV Clinical Trials",
issn = "1528-4336",
publisher = "Thomas Land Publishers Inc.",
number = "3",

}

TY - JOUR

T1 - Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients

T2 - A randomized international trial

AU - Rodriguez-Torres, Maribel

AU - Slim, Jihad

AU - Bhatti, Laveeza

AU - Sterling, Richard

AU - Sulkowski, Mark

AU - Hassanein, Tarek

AU - Serrão, Rosário

AU - Sola, Ricard

AU - Bertasso, Anne

AU - Passe, Sharon

AU - Stancic, Saray

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Background: The safety and efficacy of weight-based ribavirin (RBV) dosing regimens in patients with HIV-HCV coinfection has not been demonstrated in randomized clinical trials. Objective: This randomized, double-blind, international, parallel-group study in specialist outpatient clinics in the United States, Spain, and Portugal compares the efficacy and safety of 2 RBV dose regimens (800 mg/day and 1000/1200 mg/day) combined with peginterferon alfa-2a (40KD) in patients with HIV-HCV (genotype 1) coinfection. Methods: Patients with HIV-HCV coinfec-tion, quantifiable HCV RNA in serum, HCV genotype-1 infection, compensated liver disease, and stable HIV disease (CD4+ count ≥100 cells/μL) with or without ongoing antiretroviral therapy were randomized to 48 weeks' treatment with RBV at standard dose (800 mg/day) or weight-based dose (1000 mg/day for patients weighing

AB - Background: The safety and efficacy of weight-based ribavirin (RBV) dosing regimens in patients with HIV-HCV coinfection has not been demonstrated in randomized clinical trials. Objective: This randomized, double-blind, international, parallel-group study in specialist outpatient clinics in the United States, Spain, and Portugal compares the efficacy and safety of 2 RBV dose regimens (800 mg/day and 1000/1200 mg/day) combined with peginterferon alfa-2a (40KD) in patients with HIV-HCV (genotype 1) coinfection. Methods: Patients with HIV-HCV coinfec-tion, quantifiable HCV RNA in serum, HCV genotype-1 infection, compensated liver disease, and stable HIV disease (CD4+ count ≥100 cells/μL) with or without ongoing antiretroviral therapy were randomized to 48 weeks' treatment with RBV at standard dose (800 mg/day) or weight-based dose (1000 mg/day for patients weighing

KW - HCV

KW - HIV

KW - HIV-HCV co-infection

KW - peginterferon alfa-2a

KW - randomized controlled trial

KW - ribavirin

UR - http://www.scopus.com/inward/record.url?scp=84864323143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864323143&partnerID=8YFLogxK

U2 - 10.1310/hct1303-142

DO - 10.1310/hct1303-142

M3 - Article

C2 - 22592094

AN - SCOPUS:84864323143

VL - 13

SP - 142

EP - 152

JO - HIV Clinical Trials

JF - HIV Clinical Trials

SN - 1528-4336

IS - 3

ER -